利拉鲁肽对不同海拔地区糖调节受损肥胖患者血管内皮功能障碍的影响

发布时间：2018-03-28 07:10

本文选题：利拉鲁肽　切入点：高海拔　出处：《中国新药与临床杂志》2016年08期

【摘要】：目的观察利拉鲁肽对不同海拔地区糖调节受损肥胖患者内皮功能障碍的影响。方法选择经彩色多普勒检查血管内皮功能障碍的糖调节受损肥胖患者98例,按居住地海拔高度分为低海拔(1 780~2 999米)组(n=52)和高海拔(3 000~3 719米)组(n=46)。全部患者使用利拉鲁肽(起始剂量0.6 mg·d-1,皮下注射)治疗3个月,治疗前后检测血糖,血脂,血压,肝、肾功能等指标,使用全数字化高分辨率彩超测定肱动脉血管内皮依赖性舒张功能(FMD)。结果与治疗前比较,治疗后两组肝、肾功能,空腹血糖,餐后血糖,血脂,血压,腰臀比,糖化血红蛋白和C反应蛋白均有改善趋势,但无显著差异(P0.05);两组空腹胰岛素和稳态胰岛素评价指数水平均显著下降(P0.05),且低海拔组较高海拔组下降更为显著(P0.05)。治疗后两组FMD均显著高于治疗前(P0.05),且低海拔组高于高海拔组(P0.05),低海拔组和高海拔组分别有28例(54%)和14例(30%)患者FMD转为正常,两组相比差异显著(P0.05)。结论利拉鲁肽对不同海拔地区糖调节受损肥胖患者的血管内皮功能障碍及胰岛素抵抗均有不同程度的改善作用,且对低海拔地区患者改善作用更为显著。
[Abstract]:Objective to observe the effect of Lilaru peptide on endothelial dysfunction in obese patients with impaired glucose regulation at different altitudes. Methods 98 patients with impaired glucose regulation were examined by color Doppler. According to the altitude of the residence, the patients were divided into two groups: the low altitude group (1 780 m) and the high altitude group (3 000 ~ 3 719 m). All the patients were treated with liverrutin (initial dose 0.6 mg 路d ~ (-1) subcutaneously) for 3 months. Blood glucose, blood lipid, blood pressure, liver, liver, liver, liver and liver were measured before and after treatment. The endothelium-dependent diastolic function of brachial artery was measured by full-digital high-resolution color ultrasound. Results compared with those before treatment, liver, renal function, fasting blood glucose, postprandial blood glucose, blood lipid, blood pressure, waist-to-hip ratio were measured in two groups after treatment. Both glycosylated hemoglobin and C-reactive protein showed a trend of improvement. However, there was no significant difference between the two groups in the evaluation index of fasting insulin and steady-state insulin, and the levels of fasting insulin and steady-state insulin evaluation index in both groups were significantly lower than those in the high altitude group. After treatment, the FMD of the two groups was significantly higher than that of the pre-treatment group, and that of the low altitude group was higher than that of the low altitude group, and that of the low altitude group was higher than that of the high altitude group. In the high altitude group, there were 28 cases of P0.05A in the low altitude group and 14 cases in the high altitude group (30%). Conclusion Lilaru peptide can improve vascular endothelial dysfunction and insulin resistance in obese patients with impaired glucose regulation at different altitudes, especially in low altitude areas.
【作者单位】：青海省中医院超声科;青海省中医院内分泌科;
【分类号】：R589.2;R445.1

【相似文献】